{'fraction_non_alphanumeric': 0.019916142557651992, 'fraction_numerical': 0.013626834381551363, 'mean_word_length': 5.201298701298701, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparison of zopiclone and flurazepam treatments in insomnia

In this double‐blind study the efficacy and safety of two doses (7·5 and 11·25 mg) of zopiclone were compared to that of flurazepam (30 mg) in 60 insomniac patients divided into three groups. After an initial 4‐day washout period, placebo was administered single‐blind to all patients followed by 24 consecutive days of either one of the three drug levels. No significant difference was shown between the two zopiclone dosages at any time during the study for sleep efficacy and psychomotor performance. Compared to flurazepam, zopiclone was slightly less effective for sleep induction and sleep soundness variables. However, flurazepam was constantly worse than zopiclone for daytime performance. This study shows that both zopiclone dosages are shown to be active and safe in the treatment of insomnia, and exhibit a true advantage over flurazepam by its low incidence of residual effects.